(Yicai) Jan. 30 -- China's jab exports soared more than 50 percent last year, boosted by a growing number of shipments while prices fell.

China's vaccine exports rose 53 percent to USD324 million in 2025 from the previous year, according to data the China Chamber of Commerce for Import and Export of Medicines and Health Products released on WeChat yesterday.

Last year's growth in the value of vaccine exports was largely driven by the number of jabs being shipped, which surged 131 percent, different from the previous year, when rising prices had a bigger impact. For example, the increase in human vaccines' export value in 2024 was thanks to a 9.4 percent jump in the average unit price, which was also 34 percent higher than the level in 2019.

China's human jabs were exported to 85 markets worldwide last year, with the top 10 markets accounting for 70 percent of the total by value. Shipments to Pakistan soared 131 percent, those to Brazil 120 percent, and to Myanmar almost 30 times.

Due to the increasingly fierce competition in the Chinese jab market, more and more domestic manufacturers are accelerating their overseas expansions. Some are seizing the opportunities of industrial cooperation with countries along the Belt and Road Initiative to strengthen their market layout in developing countries and regions overseas.

Kangtai Biological Products expects its overseas income to have skyrocketed 859 percent to CNY98.8 million (USD14.2 million) last year from 2024, while its overall revenue likely only slightly increased, the Shenzhen-based company said yesterday.

On the same day, Wantai Biological Pharmacy said that to mitigate the adverse impacts on its bivalent human papillomavirus jab business, it has proactively explored international markets and accelerated the research and development and launch of innovative products, achieving certain results. Overseas income from its HPV vaccine had an "exponential growth in 2025," it noted.

Walvax Biotechnology expects its income decline in the Chinese market to have narrowed last year, while its overseas revenue likely maintained a steady growth, up about 35 percent, the Yunnan-based firm noted on Jan. 28.

Editor: Martin Kadiev